JP2013513609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513609A5 JP2013513609A5 JP2012543221A JP2012543221A JP2013513609A5 JP 2013513609 A5 JP2013513609 A5 JP 2013513609A5 JP 2012543221 A JP2012543221 A JP 2012543221A JP 2012543221 A JP2012543221 A JP 2012543221A JP 2013513609 A5 JP2013513609 A5 JP 2013513609A5
- Authority
- JP
- Japan
- Prior art keywords
- photodynamic therapy
- nanoparticles
- group
- diseases
- photosensitizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 9
- 238000002428 photodynamic therapy Methods 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003504 photosensitizing agent Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000004807 desolvation Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical group N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 230000000274 adsorptive effect Effects 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 150000004036 bacteriochlorins Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000004032 porphyrins Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960002197 temoporfin Drugs 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28590209P | 2009-12-11 | 2009-12-11 | |
| US61/285,902 | 2009-12-11 | ||
| US12/941,350 US9211283B2 (en) | 2009-12-11 | 2010-11-08 | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
| US12/941,350 | 2010-11-08 | ||
| PCT/US2010/059364 WO2011071968A2 (en) | 2009-12-11 | 2010-12-08 | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013513609A JP2013513609A (ja) | 2013-04-22 |
| JP2013513609A5 true JP2013513609A5 (enExample) | 2014-08-14 |
| JP5972171B2 JP5972171B2 (ja) | 2016-08-17 |
Family
ID=44143223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543221A Expired - Fee Related JP5972171B2 (ja) | 2009-12-11 | 2010-12-08 | 光力学的療法のためのヒト血清アルブミンをベースにしたナノ粒子キャリアシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9211283B2 (enExample) |
| EP (1) | EP2509620A4 (enExample) |
| JP (1) | JP5972171B2 (enExample) |
| CN (1) | CN102740875A (enExample) |
| BR (1) | BR112012013952A2 (enExample) |
| CA (1) | CA2784001C (enExample) |
| WO (1) | WO2011071968A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2591803A1 (de) * | 2011-11-09 | 2013-05-15 | APOCARE Pharma GmbH | Zusammensetzung für die photodynamische Diagnostik und Therapie von Tumoren |
| CN103169968B (zh) * | 2013-03-12 | 2014-11-26 | 中国科学院理化技术研究所 | 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用 |
| KR101329646B1 (ko) * | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
| EP3201201B1 (en) | 2014-09-30 | 2022-01-26 | biolitec unternehmensbeteiligungs II AG | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy |
| CN104587466B (zh) * | 2014-12-15 | 2017-11-21 | 苏州大学 | 蛋白‑聚吡咯复合物及蛋白‑聚吡咯复合物衍生物的制备方法与应用 |
| ES3011714T3 (en) | 2016-02-26 | 2025-04-08 | Biolitec Holding Gmbh & Co Kg | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy |
| DE102016125666A1 (de) * | 2016-12-23 | 2018-06-28 | Michael Denck | HSA-Galenik |
| CN111295094A (zh) | 2017-10-09 | 2020-06-16 | 泰尔茂比司特生物技术有限公司 | 冻干容器及使用冻干容器的方法 |
| EP3894421A1 (en) | 2018-12-10 | 2021-10-20 | Universität Hamburg | Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy |
| WO2020185916A1 (en) | 2019-03-14 | 2020-09-17 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| CN110251672B (zh) * | 2019-06-18 | 2022-04-01 | 深圳大学 | 一种纳米诊疗剂及其制备方法与应用 |
| CN111110861B (zh) * | 2020-02-23 | 2023-08-25 | 上海交通大学医学院附属瑞金医院 | 一种基于人血清白蛋白的载药颗粒及其制备方法 |
| CN112972676B (zh) * | 2020-08-17 | 2024-09-24 | 滨州医学院 | HSA-Biotin-DDA-TCPP分子的合成及其作为光动力治疗剂及纳米药的应用 |
| EP4225759A1 (en) * | 2020-10-05 | 2023-08-16 | biolitec Unternehmensbeteiligungs II AG | Tetrapyrrole-based compounds and their formulations for anti-microbial therapy |
| CN113855645B (zh) * | 2021-09-13 | 2024-02-02 | 苏州大学 | 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用 |
| WO2023039691A1 (zh) * | 2021-09-17 | 2023-03-23 | 苏州大学 | 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用 |
| JP2024534479A (ja) * | 2021-09-17 | 2024-09-20 | ユニバーシティ オブ メリーランド， カレッジ パーク | 非晶質光増感性粒子、その調製方法、及びその使用方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8805849D0 (en) | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9420355D0 (en) * | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
| US5648485A (en) | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| US6649192B2 (en) * | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| WO2000061584A1 (en) | 1999-04-14 | 2000-10-19 | The University Of British Columbia | IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS |
| WO2001021174A1 (en) | 1999-09-23 | 2001-03-29 | Dabur Research Foundation | Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles |
| JP2005502618A (ja) * | 2001-06-04 | 2005-01-27 | ザ・ジェネラル・ホスピタル・コーポレイション | 光力学的化合物を用いて脆弱なプラークを検出および治療する方法 |
| US7455858B2 (en) * | 2002-05-16 | 2008-11-25 | Qlt Inc. | Compositions and methods for delivery of photosensitive drugs |
| US8709449B2 (en) * | 2004-02-12 | 2014-04-29 | Biolitec Pharma Marketing Ltd | Methods and compositions for improving photodynamic therapy through administration of lipids |
| DE102004011776A1 (de) * | 2004-03-09 | 2005-11-03 | Lts Lohmann Therapie-Systeme Ag | Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen |
| JP2006056807A (ja) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | 光線力学療法製剤 |
| US20070218049A1 (en) * | 2006-02-02 | 2007-09-20 | Wei Chen | Nanoparticle based photodynamic therapy and methods of making and using same |
| US20090304803A1 (en) * | 2005-06-06 | 2009-12-10 | The General Hospital Corporation | Compositions and methods relating to target-specific photodynamic therapy |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| KR20150136137A (ko) * | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
| US8815931B2 (en) * | 2009-04-28 | 2014-08-26 | Biolitec Pharma Marketing Ltd | Oral formulations for tetrapyrrole derivatives |
| EP2425234B1 (en) * | 2009-04-30 | 2019-10-23 | Thermo Scientific Portable Analytical Instruments Inc. | Localization of an element of interest by xrf analysis of different inspection volumes |
| US20110275686A1 (en) * | 2009-12-11 | 2011-11-10 | Biolitec, Inc. | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
-
2010
- 2010-11-08 US US12/941,350 patent/US9211283B2/en active Active
- 2010-12-08 WO PCT/US2010/059364 patent/WO2011071968A2/en not_active Ceased
- 2010-12-08 CA CA2784001A patent/CA2784001C/en not_active Expired - Fee Related
- 2010-12-08 CN CN2010800629189A patent/CN102740875A/zh active Pending
- 2010-12-08 BR BR112012013952-5A patent/BR112012013952A2/en not_active IP Right Cessation
- 2010-12-08 JP JP2012543221A patent/JP5972171B2/ja not_active Expired - Fee Related
- 2010-12-08 EP EP10836582.6A patent/EP2509620A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513610A5 (enExample) | ||
| JP5972171B2 (ja) | 光力学的療法のためのヒト血清アルブミンをベースにしたナノ粒子キャリアシステム | |
| Nair et al. | Advanced drug delivery and therapeutic strategies for tuberculosis treatment | |
| JP5868869B2 (ja) | 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム | |
| Aktaş et al. | Development and brain delivery of chitosan− PEG nanoparticles functionalized with the monoclonal antibody OX26 | |
| Sarparanta et al. | Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution | |
| CA2957940C (en) | Dendrimer compositions and use in treatment of neurological and cns disorders | |
| CN105749280A (zh) | 一种协同化疗与光动力治疗的肿瘤靶向纳米给药系统的制备及应用 | |
| CN107405328B (zh) | 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用 | |
| KR102640250B1 (ko) | 암 및 안 질환의 치료를 위한 알부민 나노입자들 | |
| CN114209852B (zh) | 一种声响应型载药棒状介孔硅及其制备方法与应用 | |
| Li et al. | Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective | |
| Wang et al. | Peptide‐based supramolecular therapeutics for fighting major diseases | |
| CN109806394B (zh) | 一种介孔二氧化硅药物递送系统及其应用 | |
| Liu et al. | Protein‐Engineered Biomaterials for Cancer Theranostics | |
| CN105288646A (zh) | 一种光敏剂磷脂化合物、其药物组合物及应用 | |
| Cui et al. | Pulmonary delivery of Recombinant human bleomycin hydrolase using Mannose-Modified hierarchically porous UiO-66 for preventing bleomycin-Induced pulmonary fibrosis | |
| EP3270889A1 (en) | Targeted liposomal delivery of cgmp analogues | |
| Gu et al. | Hydrogel and nanoparticle carriers for kidney disease therapy: trends and recent advancements | |
| CN106177972B (zh) | 一种白蛋白与蒽环霉素类抗癌药的分子复合物及其制备方法 | |
| TWI708611B (zh) | 聚乙二醇化介白素-１１之組合物及方法 | |
| Singh et al. | The significance of nanomedicine in brain-targeted drug delivery: crossing blood-brain barriers | |
| CN114796514B (zh) | 水溶性正离子型超分子有机框架共价纳米仿生给药系统 | |
| ES2872223T3 (es) | Nuevo procedimiento para la preparación de forskolina soluble en agua | |
| KR101871244B1 (ko) | 광감각제를 함유하는 세포, 이의 제조방법 및 이의 용도 |